Arca
Skip to content
Tools
Tools

Hepatitis

Drug research and approvals for hepatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 258 studies of hepatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 131 drug trials for it since 2013, FDA has 14 approved and 22 open orphan designations naming it, and the EU has 26 authorised medicines for it.

  • Recruiting worldwide: 258
  • Trials authorized in Canada: 131
  • FDA orphan approvals: 14
  • EU medicines: 26

Recruiting Now

Newest start dates first, of 258 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

1 approved, 5 in phase 3, 3 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Lamivudine

Ribavirin
Phase 3 Inosine-5'-monophosphate dehydrogenase 1 inhibitor
Telbivudine
Phase 3 DNA polymerase/reverse transcriptase inhibitor
Peginterferon ALFA-2A
Phase 3 Interferon alpha/beta receptor agonist
Peginterferon ALFA-2B
Phase 3 Interferon alpha/beta receptor agonist
Pioglitazone
Phase 2 Peroxisome proliferator-activated receptor gamma agonist
Metformin
Phase 2 Mitochondrial complex I (NADH dehydrogenase) inhibitor
Fish oil triglycerides
Phase 2 Supplement
Acetaminophen
Phase 1 Cyclooxygenase inhibitor
Tenofovir disoproxil
Phase 1 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Bersacapavir
Phase 1 Core antigen modulator

How Its Trials Ended

3,626 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 1,088 whose ending is known, 58% met their primary endpoint, 6% missed it and 36% stopped early.

  • Completed, result not reported1,58244%
  • Met its primary endpoint63117%
  • Status unknown60117%
  • Ongoing35510%
  • Stopped: other or unclear2176%
  • Stopped: enrollment or feasibility913%
  • Missed its primary endpoint602%
  • Stopped: sponsor or business decision401%
  • Stopped: lack of efficacy231%
  • Stopped: safety140%
  • Stopped: funding120%

Trials Authorized in Canada

The 10 newest of 131; search them all in Canada trials
Oct 2, 2026A phase I, open-label, multi-center, dose escalation study to evaluate the safety, pk, and pd of azd6750 in participants with chronic hepatitis b on standard…AZD6750AstraZeneca PharmaceuticalsPending
Jul 22, 2026A phase 2 multi-center, randomized, open-label study to assess the efficacy and safety of ahb-137 in nucleos(t)ide analogue-treated participants with chronic…AHB-137Ausperbio Therapeutics Inc.Pending
Dec 2, 2025A phase 2/3, randomized, double-blind, multicenter, placebo-controlled study of inebilizumab in participants with autoimmune hepatitisUpliznaAmgenOngoing
May 26, 2025Phase 3, randomized, controlled, open-label study to compare the efficacy and safety of bemnifosbuvir-ruzasvir fixed-dose combination (bem/rzr fdc) versus…Bemnifosbuvir (AT-527)-RUZASVIR (AT-038)Atea Pharmaceuticals IncClosed
May 16, 2025A study to evaluate the efficacy and safety of steroid sparing strategy in immune related hepatitisPrednisone / dexamethasoneCancer Care Provincial Health CorporationOngoing
May 14, 2025A randomized, double-blind, active-controlled multicenter phase 2 study evaluating the efficacy and safety of alg-000184 compared with tenofovir disoproxil…Pevifoscorvir sodium (ALG-000184) / tenofovir disoproxilAligos Therapeutics, Inc.Ongoing
May 8, 2025A global, randomized, open-label, multicenter, phase 2b/3 trial evaluating bjt-778 vs delayed treatment for the treatment of chronic hepatitis delta infection…Brelovitug (BJT-778)Mirum PharmaceuticalsOngoing
Mar 20, 2025A phase 3 randomized, open-label study to evaluate the efficacy and safety of tobevibart+elebsiran combination therapy in participants with chronic hdv…Tobevibart (VIR-3434) / elebsiran (VIR-2218)Vir Biotechnology, Inc.Ongoing
Nov 6, 2024A double-blind, randomized, placebo-controlled, single and multiple dose study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of…AB-101Arbutus Biopharma CorporationClosed
Sep 23, 2024A phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with…Bepirovirsen (GSK3228836) / daplusiran-tomligisiran (GSK5637608/JNJ-73763989)GSKOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 36
May 22, 2026HepcludexTreatment of chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosisGilead Sciences, Inc.Approved
Jan 25, 2024KeytrudaTreatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a…MSD International Business GmbHApproved
Jun 10, 2021EpclusaTreatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6…Gilead Sciences, Inc.Approved
Jun 10, 2021MavyretTreatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection…AbbVie, Inc.Approved
Mar 19, 2020EpclusaEPCLUSA is indicated for the treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic…Gilead Sciences, Inc.Approved
Aug 28, 2019SovaldiSOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without…Gilead Sciences, Inc.Approved
Aug 28, 2019SovaldiSOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without…Gilead Sciences, Inc.Approved
Aug 28, 2019HarvoniHARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV)…Gilead Sciences, Inc.Approved
Aug 28, 2019HarvoniHARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV)…Gilead Sciences, Inc.Approved
Apr 30, 2019MavyretMAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis…AbbVie, Inc.Approved
Apr 7, 2017SovaldiTreatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without…Gilead Sciences, Inc.Approved
Apr 7, 2017HarvoniTreatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6…Gilead Sciences, Inc.Approved
Apr 6, 2007HepaGam BPrevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patientsCangene CorporationApproved
Jul 29, 2003RebetolTreatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older.Schering CorporationApproved
Oct 21, 2026BrelovitugTreatment of active hepatitis delta virus infectionMirum Pharmaceuticals, Inc.Designated

Medicines Authorised in the EU

Newest first; 15 of 26
Feb 18, 2021Heplisav BHepatitis B surface antigenDynavax GmbHEMA ↗
Jul 31, 2020HepcludexBulevirtide · orphanGilead Sciences Ireland UCEMA ↗
Sep 25, 2017Entecavir AccordEntecavir · genericAccord Healthcare S.L.U.EMA ↗
Sep 18, 2017Entecavir Viatris (previously Entecavir Mylan)Entecavir · genericViatris LimitedEMA ↗
Jul 26, 2017MaviretGlecaprevir;pibrentasvirAbbVie Deutschland GmbH & Co. KGEMA ↗
Jul 26, 2017VoseviSofosbuvir;velpatasvir;voxilapreviGilead Sciences Ireland UCEMA ↗
Jan 9, 2017VemlidyTenofovir alafenamideGilead Sciences Ireland UCEMA ↗
Jul 22, 2016ZepatierElbasvir;grazoprevirMerck Sharp & Dohme B.V.EMA ↗
Jul 6, 2016EpclusaSofosbuvir;velpatasvirGilead Sciences Ireland UCEMA ↗
Feb 15, 2016VaxelisDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)MCM Vaccine B.V.EMA ↗
Nov 17, 2014HarvoniLedispavir;sofosbuvirGilead Sciences Ireland UCEMA ↗
Jan 16, 2014SovaldiSofosbuvirGilead Sciences Ireland UCEMA ↗
Apr 17, 2013HexacimaDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)Sanofi Winthrop IndustrieEMA ↗
Apr 17, 2013HexyonDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)Sanofi Winthrop IndustrieEMA ↗
Nov 30, 2009ZutectraHuman hepatitis B immunoglobulinBiotest Pharma GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.